End of Treatment Sample Clauses

End of Treatment. (Visit 17 or Withdrawal from Study) The end of treatment for subjects completing the study is Visit 17. End of treatment testing will also be performed for subjects who are withdrawn from treatment prior to completion of the study at the time of their treatment termination. For subjects who withdraw from the study prior to completion, the site will also attempt to contact the subject at or about the 56-week time point to obtain a weight measurement, waist circumference, blood chemistry panel and xxxxx xxxxx. Activities at the end of treatment visit include: · Obtain weight and waist circumference measurements; · Obtain xxxxx xxxxx; *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. · Assess adverse events (including eye symptoms), if any; · Assess concomitant medications; · Administer ***; · Collect urine sample for pregnancy test (females of childbearing potential only) and perform pregnancy test; · Administer ***; · Administer *** and ***; · Perform *** scan ***; · Administer *** for *** and ***; · Complete End of Treatment Questions: ***; · Obtain fasting blood and urine samples for laboratory testing; · Obtain samples for biomarkers: C-reactive protein (blood), HgbA1c (blood), microalbumin (urine) and creatinine (urine); · Perform complete physical examination (including neurological examination and auscultation for heart sounds); · Perform 12-lead electrocardiogram; · Collect study medications dispensed at previous visit, assess treatment compliance and perform drug accountability;
Sample 1
AutoNDA by SimpleDocs
End of Treatment visit: three days after the last NI-0501 infusion The end of treatment visit should always be carried out 3 days (±1 day) after last NI-0501 infusion. This visit will include the following: Clinical assessment: ▪ Xxxxx xxxxx (blood pressure, oxygen saturation, heart and respiratory rate) and temperature ▪ Physical examination, including spleen and liver size (measure in cm from costal grill) as well as height and weight Procedure: ▪ ECG
Sample 1
End of Treatment. Visit 2 (Day 6)‌ With the exception of the CFRSD-CRISS administration and the blood and sputum samples for gallium and iron levels, the other Visit 2 procedures can be performed in any order in relation to the stop of the study drug infusion.
Sample 1
End of Treatment. ‌ Subjects will receive therapy until independently-confirmed disease progression per irRECIST. In the absence of significant clinical deterioration requiring intervention, disease progression identified at Week 12 should be confirmed with a repeat scan ≥ 4 weeks later and the subject should continue treatment until independent confirmation of PD based on the confirmation scan. The End of Treatment visit will be completed within 14 days of independent confirmation of radiologic PD as assessed by irRECIST (§11.3) and prior to initiation of other anti-cancer therapy. • Complete PE, including xxxxx xxxxx (T, BP, RR, HR), ECOG performance status assessment and weight if not completed within the previous 14 days • Collect blood samples for the following analyses if not completed within the previous 14 days: — CBC — Serum chemistry • Collect urine for urinalysis if not completed within the previous 14 days • 12-lead ECG • Assess adverse events and update concomitant medications • Perform CT/MRI for subjects who have not had an imaging study within the previous 4 weeks
Sample 1

Related to End of Treatment

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Fair Treatment The College and the Union agree that there shall be no discrimination, restriction, or coercion exercised or practised with respect to any employee for reason of membership or activity in the Union.

  • Denial of Preferential Tariff Treatment Except as otherwise provided in this Chapter, the importing Party may deny claim for preferential tariff treatment, if:

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • REIT Treatment The Company will use its best efforts to meet the requirements to qualify as a “real estate investment trust” under the Code for any taxable years that include any portion of the term of this Agreement.

  • National Treatment In the sectors inscribed in its Schedule, and subject to any conditions and qualifications set out therein, each Party shall accord to services and service suppliers of the other Party treatment no less favourable than that it accords, in like circumstances, to its own services and service suppliers.

  • Corporate Treatment The Board shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Board determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company’s status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Board may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a “C” corporation pursuant to the Code (a “Change in Tax Classification”), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the Service, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Board shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company no longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall no longer apply.

  • Minimum Standard of Treatment 1. Each Party shall accord to a covered investment treatment in accordance with the customary international law minimum standard of treatment of aliens, including fair and equitable treatment and full protection and security.

Time is Money Join Law Insider Premium to draft better contracts faster.